


## PHARMACEUTICAL 2022



## Checkpoint Therapeutics Inc. Rank 416 of 475





## PHARMACEUTICAL 2022



## Checkpoint Therapeutics Inc. Rank 416 of 475

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 297% points.

The company's Economic Capital Ratio, given in the ranking table, is -483%, being 207% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	55,728
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,982
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	53
Property and Equipment	0
Research and Development	48,453
Revenues	268
Selling, General and Administrative Expense	8,538

Output Variable	Value in 1000 USD
Assets	55,728
Liabilities	25,982
Expenses	56,991
Stockholders Equity	29,746
Net Income	-56,670
Comprehensive Net Income	-56,670
Economic Capital Ratio	-483%